Today: November 20, 2018, 6:32 pm
  
Business

Merus to Present at the Jefferies 2018 London Healthcare Conference

PR-Inside.com: 2018-11-08 13:02:01

UTRECHT, The Netherlands, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Ton Logtenberg, Ph.D., President and Chief Executive Officer of Merus, will present a company overview at the Jefferies 2018 London Healthcare Conference on Thursday, November 15, 2018, at 3:20 p.m. GMT.

A live webcast of the presentation will be available on the Investors and Media page of the Company's website, http://www.merus.nl. A replay of the presentation will be archived and available on the Merus website site for a limited time following the event.

About Merus N.V.

Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. Merus’ most advanced bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 2 combination trial in two metastatic breast cancer populations. MCLA-128 is also being evaluated in a Phase 1/2 clinical trial in gastric, ovarian, endometrial and non-small cell lung cancers. Additional pipeline programs include MCLA-117, which is currently being studied in a Phase 1 clinical trial in patients with acute myeloid leukemia, and MCLA-158, a Biclonics® being studied in a Phase 1 clinical trial in patients with solid tumors with an initial focus on metastatic colorectal cancer. Through its collaboration with Incyte Corporation, Merus is also developing a preclinical bispecific antibody designed to bind to PD-L1 and a non-disclosed second immunomodulatory target. For additional information, please visit Merus’ website, www.merus.nl.

Investor and Media Inquiries:

Jillian Connell
Merus N.V.
Investor Relations and Corporate Communications
617-955-4716
j.connell@merus.nl 




# 404 Words
Related Articles
More From The Author
Vectura Group announces global agreement with Hikma [..]
Vectura Group announces global agreement with Hikma to develop generic versions of GSK’s Ellipta® portfolio  Upfront payment [..]
Brookfield Asset Management Reports Third Quarter 2018 [..]
Net Income of $941 million or $0.11 per share,FFO of $1.1 billion or $1.07 per share BROOKFIELD, Nov. 08, 2018 (GLOBE [..]
flutiform® Receives a Positive Opinion in Europe [..]
The Mundipharma network of independent associated companies today announced that the European Decentralised Procedure (DCP) licence [..]
Comstock Resources, Inc. Reports Third Quarter 2018 [..]
Frisco, TX, Nov. 08, 2018 (GLOBE NEWSWIRE) -- COMSTOCK RESOURCES, INC. REPORTSTHIRD QUARTER 2018 FINANCIAL AND OPERATING RESULTS [..]
Enstar Group Limited Reports Third Quarter Results
Net Loss of $48.9 million for the Nine Months Ended September 30, 2018Non-GAAP Operating Income of $120.0 million for the Nine [..]
 
More From Business
Achieve Victory Royale With This Easy Trick [..]
Los Angeles, USA — 20 November 2018 — Buy Fortnite Account is the service that covers account purchases for the [..]
Buy LOL Account Is The Service That [..]
New York, USA — 20 November 2018 — Buy LOL Account is the service that is marketing the leading accounts [..]
Get LOL Smurfs from the Best Buy [..]
20th November 2018 - Buy Lol Smurfs provides totally amazing services for those who are in love with surfs. The [..]
Best Essential Oil Diffusers on the Market
19 November 2018 – Got Oil Supplies offers a wide variety of aromatherapy diffusers that you can choose from, depending [..]
UK Business Energy – Best Spot to [..]
London, United Kingdom – 19BNovember 2018 – UK Business Energy offers an excellent opportunity to compare all energy tariffs [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.